【摘要】 目的 探討替吉奧膠囊聯(lián)合奧沙利鉑治療晚期胃癌的近期療效和毒性反應(yīng)。 方法 2010年1-7月，16例晚期胃癌患者根據(jù)體表面積來(lái)確定初始劑量，體表面積 lt;1.25 m2，替吉奧膠囊40 mg/次，2次/d；體表面積1.25~1.5 m2，替吉奧膠囊50 mg/次，2次/d；體表面積 gt;1.5 m2，替吉奧膠囊60 mg/次，2次/d，早、晚飯后分別口服1次，連續(xù)服用28 d，停藥14 d。奧沙利鉑注射液130 mg/m2加入5%葡萄糖注射液500 mL避光緩慢靜 gt;2 h，第1、21天重復(fù)，連用2周期。按RECIST 1.1標(biāo)準(zhǔn)評(píng)價(jià)客觀療效和不良反應(yīng)。 結(jié)果 16例患者中PR 9例（56.3%），SD3例（18.8%），PD 4例（25%），總有效率為69.0%。不良反應(yīng)主要是血液學(xué)毒性、胃腸道反應(yīng)及外周神經(jīng)毒性，且均在Ⅰ~Ⅱ。 結(jié)論 替吉奧膠囊聯(lián)合奧沙利鉑方案治療晚期胃癌的近期療效較好，不良反應(yīng)可以耐受，值得進(jìn)一步研究應(yīng)用。
【Abstract】 Objective To explore the early efficacy of Oxaliplatin combined with S1 capsule on advanced gastric cancer and observe the toxicity. Methods A total of 16 patients with advanced gastric cancer from January to July 2010 were treated with chemotherapy: oxaliplatin 130 mg/m2 mixed with 5% glucose injection 500 mL in the first day and repeated in the 21st day; Po after breakfast and dinner: S1 capsule with an initial dose according to the body surface area. Body surface lt;1.25 m2, 40 mg once, twice per day; body surface:1.25-1.5 m2,50 mg once, twice per day; body surface gt;1.5 m2, 60 mg once, twice per day. The medication lasted for 28 days, withdrew for 14 days. All of the patients underwent the treatment for two cycles. Efficacy and toxicities were evaluated according to the RECIST 1.1 standard. Results Of the 16 patients, partial remission (PR) was in nine (56.3%), stable disease was in three (18.8%) (SD), and progression disease was in four (PD). The total response rate was 69.0%. The major toxicities included leucopenia, nausea, vomiting and neurosensory abnormity. Conclusion Oxaliplatin combined with S1 capsule is effective on advanced gastric cancer, and the adverse effects are tolerable.
引用本文： 何建萍,易成,李秋,畢鋒,許峰. 替吉奧膠囊聯(lián)合奧沙利鉑治療晚期胃癌的臨床觀察. 華西醫(yī)學(xué), 2010, 25(11): 1947-1949. doi: 復(fù)制
| 1. | 孫燕, 石元?jiǎng)P. 臨床腫瘤內(nèi)科手冊(cè)[M]. 5版. 北京: 人民衛(wèi)生出版社, 2007: 476-477. |
| 2. | 湯釗猷. 現(xiàn)代腫瘤學(xué)[M]. 2版, 上海: 上海醫(yī)科大學(xué)出版社, 2000: 730-731. |
| 3. | Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J]. Curr Pharm Biotechnol, 2000, 1(2): 137-164. |
| 4. | Malet-Martino M, Martion R. Clinical studies of three oral prodrugs of 5 fluorouracil (capecitabine, UFT, s-1): a review[J]. Oncologist, 2002, 7(4): 288-323. |
| 5. | Koizumi W, Kurhara M, Nakano S. PhaseⅡstudy of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastic cancer. Oncology (Basel), 2000, 58(3): 191-197. |
| 6. | Chollet P, Schoffski P, Weigang-Kohler K. Phase Ⅱ trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)[J]. Eur J Cancer, 2003, 39(9): 1264-1270. |
| 7. | Koizumi W, Tanabe S, Saigenji K. Gotoh M: phaseⅠ/Ⅱstudy of S-1 combined with cisplatin in patients with advanced gastric cancer[J]. Br J Cancer, 2003, 89(12): 2207-2212. |
| 8. | 馬培奇. 抗腫瘤新藥替吉奧鉀研究進(jìn)展[J]. 中國(guó)醫(yī)藥導(dǎo)刊, 2007, 9(6): 499-502. |
| 9. | 白坂哲彥, 佃守, 犬山征夫他. 新規(guī)經(jīng)口抗癌劑TS-l(S-1)[J]. 癌匕化學(xué)療法, 2001, 28(6): 855-864. |
| 10. | Mschars Y, S-1 in gastric cancer: a comprehensive review. Gastric Cancer, 2003, 6(Suppl 1): 2-8. |
| 11. | Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity[J]. Sernin Oncol, 1998, 25(2 Suppl 5): 4-12. |
| 12. | Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrunm of activity in drugresistant cell lines and in the cell lines of the National Cancer Institute′s Anticancer Drug Screen panel[J]. Biochem Pharmacol, 1996, 52(12): 1855-1865. |
| 13. | 廖子君, 南克俊, 韓軍. 現(xiàn)代腫瘤治療藥物學(xué)[M]. 西安: 世界圖書(shū)出版西安公司, 2002: 290-291. |
| 14. | 金懋林, 陳強(qiáng), 程風(fēng)歧, 等. 奧沙利鉑聯(lián)合亞葉酸鈣和5-氟尿嘧啶治療晚期胃癌的研究[J]. 中華腫瘤雜志, 2003, 25(2): 172-174. |
- 1. 孫燕, 石元?jiǎng)P. 臨床腫瘤內(nèi)科手冊(cè)[M]. 5版. 北京: 人民衛(wèi)生出版社, 2007: 476-477.
- 2. 湯釗猷. 現(xiàn)代腫瘤學(xué)[M]. 2版, 上海: 上海醫(yī)科大學(xué)出版社, 2000: 730-731.
- 3. Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J]. Curr Pharm Biotechnol, 2000, 1(2): 137-164.
- 4. Malet-Martino M, Martion R. Clinical studies of three oral prodrugs of 5 fluorouracil (capecitabine, UFT, s-1): a review[J]. Oncologist, 2002, 7(4): 288-323.
- 5. Koizumi W, Kurhara M, Nakano S. PhaseⅡstudy of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastic cancer. Oncology (Basel), 2000, 58(3): 191-197.
- 6. Chollet P, Schoffski P, Weigang-Kohler K. Phase Ⅱ trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)[J]. Eur J Cancer, 2003, 39(9): 1264-1270.
- 7. Koizumi W, Tanabe S, Saigenji K. Gotoh M: phaseⅠ/Ⅱstudy of S-1 combined with cisplatin in patients with advanced gastric cancer[J]. Br J Cancer, 2003, 89(12): 2207-2212.
- 8. 馬培奇. 抗腫瘤新藥替吉奧鉀研究進(jìn)展[J]. 中國(guó)醫(yī)藥導(dǎo)刊, 2007, 9(6): 499-502.
- 9. 白坂哲彥, 佃守, 犬山征夫他. 新規(guī)經(jīng)口抗癌劑TS-l(S-1)[J]. 癌匕化學(xué)療法, 2001, 28(6): 855-864.
- 10. Mschars Y, S-1 in gastric cancer: a comprehensive review. Gastric Cancer, 2003, 6(Suppl 1): 2-8.
- 11. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity[J]. Sernin Oncol, 1998, 25(2 Suppl 5): 4-12.
- 12. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrunm of activity in drugresistant cell lines and in the cell lines of the National Cancer Institute′s Anticancer Drug Screen panel[J]. Biochem Pharmacol, 1996, 52(12): 1855-1865.
- 13. 廖子君, 南克俊, 韓軍. 現(xiàn)代腫瘤治療藥物學(xué)[M]. 西安: 世界圖書(shū)出版西安公司, 2002: 290-291.
- 14. 金懋林, 陳強(qiáng), 程風(fēng)歧, 等. 奧沙利鉑聯(lián)合亞葉酸鈣和5-氟尿嘧啶治療晚期胃癌的研究[J]. 中華腫瘤雜志, 2003, 25(2): 172-174.